We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

AXA Diagnostics Showcases SkyLAB752 ELISA Analyzer

By LabMedica International staff writers
Posted on 09 Feb 2017
Image: The SkyLAB752 ELISA analyzer (Photo courtesy of AXA Diagnostics).
Image: The SkyLAB752 ELISA analyzer (Photo courtesy of AXA Diagnostics).
AXA Diagnostics, part of Dasit Group S.p.A., which owns several companies in the fields of in-vitro diagnostics and life sciences, showcased updates and new applications of the SkyLAB752 system, its platform for ELISA and IFA automation, at MEDLAB 2017 held in Dubai, UAE from February 6-9, 2017.

Italy-based AXA Diagnostics develops, produces, and markets IVD reagents dedicated to autoimmunity diseases and instruments for the automation of all ELISA and IFA testing. The company’s SkyLAB752 fully automated analyzer can process up to 7 ELISA microplates or up to 28 IFA slides per each working session. The SkyLAB752 is equipped with two innovative dispensing systems that work simultaneously and independently, allowing ELISA and IFA assays to be processed simultaneously in the same working session.

The instrument’s architecture is designed to make it adaptable to processing even the greatest workloads. Designed to be easily integrated with a pre-analytical system, the flexibility of its working area allows the SkyLAB 752 to meet the wide requirements of each lab. At MEDLAB 2017, AXA Diagnostics also showcased reagent kits of its autoimmunity product line, which provides a wide choice of analytical techniques for performing both screening and confirmation testing, as well as allows patients’ follow up. This included ELISA reagent kits for the detection of specific auto-antibodies of the main classes (IgG, IgM and IgA) and their combinations, which are indicative of specific pathological conditions. It also included DOT BLOT reagent kits comprising numerous antigenic profiles for the confirmation of systemic autoimmune and organ specific diseases with several specific pathology markers.

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Clinical Informatics Platform
CLARION™
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA

Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more